803 related articles for article (PubMed ID: 26828775)
21. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.
Tantawy M; Pamittan FG; Singh S; Gong Y
Clin Transl Sci; 2021 Jan; 14(1):36-46. PubMed ID: 32770710
[TBL] [Abstract][Full Text] [Related]
23. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
24. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
[TBL] [Abstract][Full Text] [Related]
25. [Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention].
Andrieu-Abadie N
Therapie; 2004; 59(1):121-6. PubMed ID: 15199678
[TBL] [Abstract][Full Text] [Related]
26. Ranolazine in the prevention of anthracycline cardiotoxicity.
Corradi F; Paolini L; De Caterina R
Pharmacol Res; 2014 Jan; 79():88-102. PubMed ID: 24269342
[TBL] [Abstract][Full Text] [Related]
27. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
[TBL] [Abstract][Full Text] [Related]
28. Role of mtDNA lesions in anthracycline cardiotoxicity.
Lebrecht D; Walker UA
Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
[TBL] [Abstract][Full Text] [Related]
29. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
[TBL] [Abstract][Full Text] [Related]
30. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial Sirtuins and Doxorubicin-induced Cardiotoxicity.
He L; Liu F; Li J
Cardiovasc Toxicol; 2021 Mar; 21(3):179-191. PubMed ID: 33438065
[TBL] [Abstract][Full Text] [Related]
32. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
[TBL] [Abstract][Full Text] [Related]
33. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
34. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.
Salvatorelli E; Menna P; Minotti G
Future Cardiol; 2015 Jul; 11(4):363-6. PubMed ID: 26239550
[No Abstract] [Full Text] [Related]
35. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Aspects of Anthracycline Cardiotoxicity.
Russo M; Della Sala A; Tocchetti CG; Porporato PE; Ghigo A
Curr Treat Options Oncol; 2021 Feb; 22(2):18. PubMed ID: 33547494
[TBL] [Abstract][Full Text] [Related]
37. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities.
Li M; Russo M; Pirozzi F; Tocchetti CG; Ghigo A
Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118493. PubMed ID: 31233802
[TBL] [Abstract][Full Text] [Related]
38. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.
Fulbright JM; Egas-Bejar DE; Huh WW; Chandra J
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1297-307. PubMed ID: 26515054
[TBL] [Abstract][Full Text] [Related]
39. Anthracycline and Peripartum Cardiomyopathies.
Cowgill JA; Francis SA; Sawyer DB
Circ Res; 2019 May; 124(11):1633-1646. PubMed ID: 31120822
[TBL] [Abstract][Full Text] [Related]
40. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]